NCT03045016View on ClinicalTrials.gov

Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 21, 2017

Primary Completion Date

March 30, 2020

Study Completion Date

March 30, 2020

Conditions
Acute Stress Disorder
Interventions
DRUG

Prazosin, ALPRESS® LP 2,5 et 5 mg

"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."

Trial Locations (1)

69003

Groupement Hospitalier Edouard Herriot - Emergency Psychiatry Department, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT03045016 - Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder | Biotech Hunter | Biotech Hunter